Biotech Tweet of the Week: Investing in Moldy Pizza

Our tweet of the week comes from Luke Timmerman, quoting Oleg Nodelman, founder and managing director of EcoR1 Capital, a value-oriented health-care investment fund. During a panel at Allicense, Nodelman commented that you can invest in a moldy piece of pizza if it's biologically active and has a 10% chance of working; it's just a question of valuation.

While investing in something that is likely to fail may seem counterintuitive, it's OK to make the investment as long as the potential upside justifies the risk. If a clinical trial only has a 1-in-10 chance of success, but the company will be valued 20 times higher if the trial is successful, that's actually a good investment. Investors just have to adjust the size of their investment appropriately, because there's a good chance the investment could be worthless after the binary event.

In the current market, with everything valued so high relative to where it was a year ago, it's hard to find these kinds of opportunities. But historically you can find examples like Aeterna Zentaris and Keryx Biopharmaceuticals (NASDAQ: KERX  ) that had a colorectal cancer drug, perifosine, in a phase 3 trial based on a subset of the phase 2 data. The chances for success were unknown, but both companies were priced low enough that they seemed worthy of an investment.

As senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss in the following video, the best investors were able to buy the companies' moldy pizza when it was cheap and then sell it after the shares appreciated before the data was released.

Another example, MannKind (NASDAQ: MNKD  ) , was obviously a good investment when it was left for dead under $2 a couple of years ago. Even if investors missed selling at the highs last August after the latest phase 3 data was released, they're still sitting on a 300% or more gain over just two years.

Based on his "don't lose money" rule, Warren Buffett would hate this strategy
Admittedly, investing in companies with low probabilities of monster returns isn't for everyone. If Warren Buffett's strategy is more your speed, check out our exclusive, brand-new Motley Fool report details one of Buffett's recent purchases that already has over 50% market share. Just click here to discover more about this industry-leading stock, and join Buffett in his quest for a veritable landslide of profits!


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 19, 2014, at 10:23 PM, Butcher594 wrote:

    Dr. Orelli... not sure what medical school you hail from, obviously not mine. Maybe you should ask for your money back. MannKind? Really? And to the silly question as to why I am cancelling my subscription to Motley Fool...

    Enough is enough... what a shame!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2963723, ~/Articles/ArticleHandler.aspx, 10/25/2014 3:52:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement